{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:45:34Z","timestamp":1792010734844,"version":"4.4.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","award":["2024-3-1553"],"award-info":[{"award-number":["2024-3-1553"]}],"id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002956","name":"Foundation for Women&apos;s Cancer","doi-asserted-by":"publisher","award":["2025-2026"],"award-info":[{"award-number":["2025-2026"]}],"id":[{"id":"10.13039\/100002956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021369","name":"OCRA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021369","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ygyno.2026.10.005","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:57:56Z","timestamp":1791939476000},"page":"59-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A second chance? Outcomes of immunotherapy retreatment after prior checkpoint inhibitor exposure in endometrial and cervical cancer"],"prefix":"10.1016","volume":"214","author":[{"given":"Julia","family":"Chalif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Coon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Abdeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey M.","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa I.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ygyno.2026.10.005_bb0005","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2026.10.005_bb0010","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ygyno.2026.10.005_bb0015","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.10.005_bb0020","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","author":"Lorusso","year":"2024","journal-title":"Lancet. Published online March 20"},{"key":"10.1016\/j.ygyno.2026.10.005_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1475502","article-title":"Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis","volume":"14","author":"Cao","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.005_bb0030","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11912-022-01241-z","article-title":"Immune checkpoint inhibitor Rechallenge and resumption: a systematic review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2026.10.005_bb0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2021.07.002","article-title":"The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients","volume":"155","author":"Zaremba","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.005_bb0040","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of immune checkpoint inhibitors after immune-related adverse events in patients with Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.005_bb0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/AOG.0000000000005243","article-title":"Evaluation of efficacy and adverse events after second immunotherapy exposure in endometrial and cervical carcinoma","volume":"142","author":"Morton","year":"2023","journal-title":"Obstet. Gynecol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.10.005_bb0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3349\/ymj.2023.0063","article-title":"Rechallenge with anti-PD-1 inhibitors in patients with recurrent gynecologic malignancies","volume":"64","author":"Kim","year":"2023","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.ygyno.2026.10.005_bb0055","article-title":"Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: a case series","volume":"50","author":"Rose","year":"2023","journal-title":"Gynecol Oncol Rep."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.005_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004233","article-title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","volume":"10","author":"Lheureux","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.005_bb0065","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1093\/oncolo\/oyae134","article-title":"Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.005_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102124","article-title":"Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy","volume":"35","author":"Podder","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.005_bb0075","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for advanced endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.10.005_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the Rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with Cancer: a systemic review and Meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2026.10.005_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103434","article-title":"Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"165","author":"Inno","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.005_bb0090","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: Management of Immunotherapy-Related Toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.005_bb0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor Rechallenge after immune-related adverse events in patients with Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:59:32Z","timestamp":1792007972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"alternative-id":["S0090825826021566"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A second chance? Outcomes of immunotherapy retreatment after prior checkpoint inhibitor exposure in endometrial and cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}